Literature DB >> 28283278

Sex differences in the efficacy, safety, and tolerability of omalizumab after 1 year in Maltese patients with asthma.

Caroline Gouder1, Rachelle Asciak2, Stephen Montefort2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28283278     DOI： 10.1016/j.anai.2017.01.019

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  2 in total

1.  Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.

Authors:  Maria Maddalena Sirufo; Enrica Maria Bassino; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

Review 2.  Sex, Allergic Diseases and Omalizumab.

Authors:  Maria Maddalena Sirufo; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis
Journal:  Biomedicines       Date:  2022-01-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.